Gleam of hope continues to hit the world after another second US made Covid-19 vaccine is announced.
The drug which has been scientifically rated at 94.5 effective, was made public by a US based Moderna firm which is one of the respected research companies in US.
According to The Guardian, the drug has a long shelf life as well as affordable storage stability across the globe.
The publication further showed that an interim analysis released on Monday, and based on the first 95 patients with confirmed Covid infections, found the candidate vaccine has an efficacy of 94.5%.
If this drug is finally approved, Third World countries will have however to wait until end of next year to receive their first order. This is according to Dr. Walter Aoko from Nairobi University who was speaking to Citizen Tv on Monday November 16th.
Moderna company is now in the race to apply to the US regulator, the Food and Drug Administration, for emergency-use authorisation in the coming weeks.
“The results are the latest encouraging news to emerge from the breakneck effort to develop a vaccine against coronavirus and follow a similar interim analysis earlier this month from a collaboration between Pfizer and German firm Biotech who came up with a vaccine that is 90 percent effective,” The Guardian reported on Monday November 16th.
The biotech company said it would have 20m doses ready to ship in the US before the end of 2020 and hoped to manufacture another 500m to 1bn doses globally next year.